Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10818929 | 0.95 | SIGMAR1 (0.43) | CSNK1ESIGMAR1 | |
| SCHEMBL28475117 | 0.83 | CSNK1E (0.50) | CSNK1ESIGMAR1 | |
| SCHEMBL3033446 | 0.81 | KCNH2 (0.44) | CSNK1ESIGMAR1HTR2A | |
| SCHEMBL27624451 | 0.78 | TDP1 (0.47) | HTR2A | |
| SCHEMBL8726699 | 0.78 | EPHX1 (0.50) | CSNK1ESIGMAR1 | |
| SCHEMBL5605740 | 0.77 | PLA2G2A (0.50) | — | |
| SCHEMBL5606109 | 0.77 | PLA2G2A (0.50) | — | |
| SCHEMBL9747898 | 0.76 | KCNH2 (0.43) | SIGMAR1HTR2A | |
| Isopropylamine SCHEMBL1648067 | 0.75 | HTR2A (0.62) | CSNK1ESIGMAR1S1PR2S1PR1HTR2A | |
| SCHEMBL19511373 | 0.75 | MEN1 (0.46) | CSNK1ESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032555-A1 | Novel aryloxyphenyl-propanamines | CONCERT PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032555-A1 | Novel aryloxyphenyl-propanamines | SLC6A2, SLC6A3, SLC18A1 | CSNK1E 2356/4885SIGMAR1 48/4885S1PR2 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.